Type 2 inflammation: a Portuguese consensus using Web-Delphi and decision conferencing (INFLAT2-PT).

IF 3.9 3区医学 Q2 IMMUNOLOGY

Expert Review of Clinical Immunology Pub Date : 2025-01-02 DOI:10.1080/1744666X.2024.2448990

Suzete Costa, João Pedro Aguiar, Mónica D Oliveira, João Gonçalves, João Carlos Ribeiro, Luís Taborda-Barata, Helena Farinha, Pedro Escada, Samuel Fernandes, Luís Soares-de-Almeida, Maria João Paiva-Lopes, Cláudia Chaves Loureiro, Isabel Lourinho, João A Fonseca, Marta Drummond, Rui Tato Marinho, João Bana E Costa, António Vaz Carneiro, Carlos A Bana E Costa

{"title":"Type 2 inflammation: a Portuguese consensus using Web-Delphi and decision conferencing (INFLAT2-PT).","authors":"Suzete Costa, João Pedro Aguiar, Mónica D Oliveira, João Gonçalves, João Carlos Ribeiro, Luís Taborda-Barata, Helena Farinha, Pedro Escada, Samuel Fernandes, Luís Soares-de-Almeida, Maria João Paiva-Lopes, Cláudia Chaves Loureiro, Isabel Lourinho, João A Fonseca, Marta Drummond, Rui Tato Marinho, João Bana E Costa, António Vaz Carneiro, Carlos A Bana E Costa","doi":"10.1080/1744666X.2024.2448990","DOIUrl":null,"url":null,"abstract":"Objectives: Atopic/allergic diseases impose a growing burden on public health, affecting millions of patients worldwide. The main objective of this study was to develop a national expert consensus on relevant clinical questions related to type 2 inflammation.Methods: We conducted: a comprehensive literature review with a qualitative analysis to identify the most repeated themes on the overlap of conditions; a modified 3-round Web-Delphi (or e-Delphi); and a final online decision conference.Results: We included 51 studies. Following three Web-Delphi rounds, we ended up with 30 statements with a 76% overall full agreement rate, 16% agreement, 2% disagreement, and 0% full disagreement. The decision conference enabled adjustments, and the expert panel agreed unanimously on the final set of statements. The consensus used evidence synthesis, Web-Delphi, and decision conference to produce 30 statements on type 2 inflammation as a driver for multimorbidity in asthma, certain rhinitis phenotypes, atopic dermatitis, chronic rhinosinusitis with nasal polyps, and eosinophilic esophagitis grouped under five domains in underlying pathophysiology, multimorbidity, diagnosis and management, multidisciplinary management, and impact on mental health.Conclusion: We expect the first Portuguese expert consensus INFLAT2-PT to promote understanding of type 2 inflammation diseases, multidisciplinary care, integrated care pathways, future research, and inform health authorities.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":""},"PeriodicalIF":3.9000,"publicationDate":"2025-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Clinical Immunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/1744666X.2024.2448990","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: Atopic/allergic diseases impose a growing burden on public health, affecting millions of patients worldwide. The main objective of this study was to develop a national expert consensus on relevant clinical questions related to type 2 inflammation.

Methods: We conducted: a comprehensive literature review with a qualitative analysis to identify the most repeated themes on the overlap of conditions; a modified 3-round Web-Delphi (or e-Delphi); and a final online decision conference.

Results: We included 51 studies. Following three Web-Delphi rounds, we ended up with 30 statements with a 76% overall full agreement rate, 16% agreement, 2% disagreement, and 0% full disagreement. The decision conference enabled adjustments, and the expert panel agreed unanimously on the final set of statements. The consensus used evidence synthesis, Web-Delphi, and decision conference to produce 30 statements on type 2 inflammation as a driver for multimorbidity in asthma, certain rhinitis phenotypes, atopic dermatitis, chronic rhinosinusitis with nasal polyps, and eosinophilic esophagitis grouped under five domains in underlying pathophysiology, multimorbidity, diagnosis and management, multidisciplinary management, and impact on mental health.

Conclusion: We expect the first Portuguese expert consensus INFLAT2-PT to promote understanding of type 2 inflammation diseases, multidisciplinary care, integrated care pathways, future research, and inform health authorities.

查看原文本刊更多论文

2型炎症：使用Web-Delphi和决策会议（INFLAT2-PT）的葡萄牙共识。

目标：特应性/过敏性疾病对公共卫生造成越来越大的负担，影响到全世界数百万患者。本研究的主要目的是就与2型炎症相关的临床问题达成全国专家共识。方法：我们进行了全面的文献综述和定性分析，以确定重复最多的主题重叠的条件；改进的3轮Web-Delphi（或e-Delphi）；以及最后的在线决策会议。结果：我们纳入了51项研究。经过三轮Web-Delphi，我们最终得到了30个陈述，总体完全同意率为76%，同意率为16%，不同意率为2%，完全不同意率为0%。决策会议允许进行调整，专家小组一致同意最后一组声明。该共识通过证据综合、Web-Delphi和决策会议产生了30份关于2型炎症作为哮喘、某些鼻炎表型、特应性皮炎、慢性鼻窦炎伴鼻息肉和嗜酸性粒细胞性食管炎的驱动因素的声明，这些声明在潜在病理生理学、多发病、诊断和管理、多学科管理和对心理健康的影响方面分为五个领域。结论：我们期望首次葡萄牙专家共识INFLAT2-PT能够促进对2型炎症疾病、多学科护理、综合护理途径、未来研究的理解，并告知卫生当局。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Clinical Immunology IMMUNOLOGY-

CiteScore

7.60

自引率

2.30%

发文量

221

审稿时长

6-12 weeks

期刊介绍： Expert Review of Clinical Immunology (ISSN 1744-666X) provides expert analysis and commentary regarding the performance of new therapeutic and diagnostic modalities in clinical immunology. Members of the International Editorial Advisory Panel of Expert Review of Clinical Immunology are the forefront of their area of expertise. This panel works with our dedicated editorial team to identify the most important and topical review themes and the corresponding expert(s) most appropriate to provide commentary and analysis. All articles are subject to rigorous peer-review, and the finished reviews provide an essential contribution to decision-making in clinical immunology. Articles focus on the following key areas: • Therapeutic overviews of specific immunologic disorders highlighting optimal therapy and prospects for new medicines • Performance and benefits of newly approved therapeutic agents • New diagnostic approaches • Screening and patient stratification • Pharmacoeconomic studies • New therapeutic indications for existing therapies • Adverse effects, occurrence and reduction • Prospects for medicines in late-stage trials approaching regulatory approval • Novel treatment strategies • Epidemiological studies • Commentary and comparison of treatment guidelines Topics include infection and immunity, inflammation, host defense mechanisms, congenital and acquired immunodeficiencies, anaphylaxis and allergy, systemic immune diseases, organ-specific inflammatory diseases, transplantation immunology, endocrinology and diabetes, cancer immunology, neuroimmunology and hematological diseases.